Greenwich LifeSciences (GLSI) said Wednesday that the European Medicines Agency has approved its application to add 11 new sites in Spain, Germany, and Poland for a late-stage trial of GLSI-100 to prevent breast cancer recurrences.
The company said that with the latest approval, regulators have cleared the way for the activation of 110 to 115 sites in Europe.
Greenwich said it plans to file applications with the EMA to add 5 to 10 additional sites in Ireland, Romania, and potentially other European countries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.